We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GMED Stock Might Rise From the Commercial Launch of Its ExcelsiusHub
Read MoreHide Full Article
Globus Medical, Inc. (GMED - Free Report) recently made a commercial launch of the ExcelsiusHub navigation system. ExcelsiusHub offers advantageous features designed to enhance spine navigation's safety and reproducibility, such as real-time patient array monitoring, tissue-sparing drills and registration flexibility. ExcelsiusHub is an addition to the expansive ecosystem of Excelsius technologies.
The latest launch expands the company’s Enabling Technologies product category.
GMED’s Likely Stock Trend Following the News
Subsequent to the news, GMED's share price moved south 0.6% to $84.24 in aftermarket trading on Friday.
Globus Medical is gaining high-level synergy from the continuously increasing adoption of its ExcelsiusGPS robot and Excelsius3D imaging systems in spinal surgery. Additionally, the third quarter of 2024 marked a record for total Excelsius units placed. Moreover, the recent launch of ExcelsiusHub broadens the company’s offering within the intraoperative navigation platform for implant placement accuracy and surgical efficiency space. Accordingly, we expect market sentiment to return in favor of GMED stock in the upcoming days.
Globus Medical boasts a market capitalization of $11.54 billion. The company delivered an average earnings surprise of 17.65% in the trailing four quarters.
About GMED’s ExcelsiusHub
Globus Medical’s ExcelsiusHub is designed to elevate the standard for freehand navigation. Freehand navigation provides surgeons with real-time visualization of instrument placement to reduce the reliance on X-ray imaging during spine surgery. This also facilitates the accurate placement of screws and interbody spacer implants and can also reduce OR radiation when compared to conventional fluoroscopy.
ExcelsiusHub offers several differentiated functionalities, including elevated safety features paired with navigational accuracy, designed to enhance patient safety, such as patient array shift tracking and navigation of the DuraPro Oscillating System. It also offers imaging versatility with three distinct workflows — automatic registration with Excelsius3D, CT to fluoroscopy merging, and intraoperative 2D navigation. ExcelsiusHub is designed to navigate best-in-class Globus Medical instruments and implants for a complete procedural solution from the cervical spine to the sacrum.
ExcelsiusHub supports a variety of procedures, from minimally invasive to complex spinal deformity surgeries. Moreover, the newly launched ExcelsiusHub is a technological enhancement aimed at improving efficiency in operating rooms and surgical solutions for patients.
Industry Prospects Favor GMED
Per a report by Insight Partners, the surgical navigation systems market size is expected to grow $2.46 billion by 2030 at a compound annual growth rate of 10.09% from 2022 to 2030. Key factors responsible for market growth include the expanding demand for robot-assisted surgery, the growing need for minimally invasive surgical procedures and the rising prevalence of target disorders.
Image Source: Zacks Investment Research
Another Recent Development by GMED
The previous month, Globus Medical reported the expansion of its rapidly growing orthopedic trauma product portfolio. The newly launched next-generation systems include ANTHEM II Distal Radius Volar Plates, AUTOBAHN Trochanteric Nail PRO Instruments and CAPTIVATE SOLA Headless Screws. With these newly launched next-gen products, the company now has more capacity to serve a wide variety of patient needs depending upon its new technologies building out the orthopedic trauma product portfolio.
GMED’s Share Price Performance
In the past year, GMED’s shares have risen 83.9% compared with the industry’s 14.8% growth.
GMED’s Zacks Rank and Other Key Picks
Globus Medical currently carries a Zacks Rank #2 (Buy).
Haemonetics has an earnings yield of 5.02% compared with the industry’s 1.18%. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 19.39%. Its shares have risen 1.8% compared with the industry’s 23.1% growth in the past year. Estimates for Haemonetics’ 2025 EPS have moved north 0.4% to $4.59 in the past 30 days.
Estimates for Penumbra’s 2024 EPS have moved north 8.1% to $2.79 in the past 30 days. Shares of the company have surged 60.6% in the past year compared with the industry’s growth of 32.7%. PEN’s earnings surpassed estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 10.54%.
Estimates for ResMed’s fiscal 2025 EPS have risen 2.7% in the past 30 days. Shares of the company have surged 86.3% in the past year compared with the industry’s 32.1% growth. RMD’s earnings surpassed estimates in each of the trailing four quarters, the average beat being 6.4%. In the last reported quarter, it delivered an earnings surprise of 8.4%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
GMED Stock Might Rise From the Commercial Launch of Its ExcelsiusHub
Globus Medical, Inc. (GMED - Free Report) recently made a commercial launch of the ExcelsiusHub navigation system. ExcelsiusHub offers advantageous features designed to enhance spine navigation's safety and reproducibility, such as real-time patient array monitoring, tissue-sparing drills and registration flexibility. ExcelsiusHub is an addition to the expansive ecosystem of Excelsius technologies.
The latest launch expands the company’s Enabling Technologies product category.
GMED’s Likely Stock Trend Following the News
Subsequent to the news, GMED's share price moved south 0.6% to $84.24 in aftermarket trading on Friday.
Globus Medical is gaining high-level synergy from the continuously increasing adoption of its ExcelsiusGPS robot and Excelsius3D imaging systems in spinal surgery. Additionally, the third quarter of 2024 marked a record for total Excelsius units placed. Moreover, the recent launch of ExcelsiusHub broadens the company’s offering within the intraoperative navigation platform for implant placement accuracy and surgical efficiency space. Accordingly, we expect market sentiment to return in favor of GMED stock in the upcoming days.
Globus Medical boasts a market capitalization of $11.54 billion. The company delivered an average earnings surprise of 17.65% in the trailing four quarters.
About GMED’s ExcelsiusHub
Globus Medical’s ExcelsiusHub is designed to elevate the standard for freehand navigation. Freehand navigation provides surgeons with real-time visualization of instrument placement to reduce the reliance on X-ray imaging during spine surgery. This also facilitates the accurate placement of screws and interbody spacer implants and can also reduce OR radiation when compared to conventional fluoroscopy.
ExcelsiusHub offers several differentiated functionalities, including elevated safety features paired with navigational accuracy, designed to enhance patient safety, such as patient array shift tracking and navigation of the DuraPro Oscillating System. It also offers imaging versatility with three distinct workflows — automatic registration with Excelsius3D, CT to fluoroscopy merging, and intraoperative 2D navigation. ExcelsiusHub is designed to navigate best-in-class Globus Medical instruments and implants for a complete procedural solution from the cervical spine to the sacrum.
ExcelsiusHub supports a variety of procedures, from minimally invasive to complex spinal deformity surgeries. Moreover, the newly launched ExcelsiusHub is a technological enhancement aimed at improving efficiency in operating rooms and surgical solutions for patients.
Industry Prospects Favor GMED
Per a report by Insight Partners, the surgical navigation systems market size is expected to grow $2.46 billion by 2030 at a compound annual growth rate of 10.09% from 2022 to 2030. Key factors responsible for market growth include the expanding demand for robot-assisted surgery, the growing need for minimally invasive surgical procedures and the rising prevalence of target disorders.
Image Source: Zacks Investment Research
Another Recent Development by GMED
The previous month, Globus Medical reported the expansion of its rapidly growing orthopedic trauma product portfolio. The newly launched next-generation systems include ANTHEM II Distal Radius Volar Plates, AUTOBAHN Trochanteric Nail PRO Instruments and CAPTIVATE SOLA Headless Screws. With these newly launched next-gen products, the company now has more capacity to serve a wide variety of patient needs depending upon its new technologies building out the orthopedic trauma product portfolio.
GMED’s Share Price Performance
In the past year, GMED’s shares have risen 83.9% compared with the industry’s 14.8% growth.
GMED’s Zacks Rank and Other Key Picks
Globus Medical currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the broader medical space are Haemonetics (HAE - Free Report) , Penumbra (PEN - Free Report) , and ResMed (RMD - Free Report) . While ResMed sports a Zacks Rank #1 (Strong Buy) at present, Haemonetics and Penumbra carry a Zacks Rank #2 each. You can see the complete list of today’s Zacks #1 Rank stocks here.
Haemonetics has an earnings yield of 5.02% compared with the industry’s 1.18%. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 19.39%. Its shares have risen 1.8% compared with the industry’s 23.1% growth in the past year. Estimates for Haemonetics’ 2025 EPS have moved north 0.4% to $4.59 in the past 30 days.
Estimates for Penumbra’s 2024 EPS have moved north 8.1% to $2.79 in the past 30 days. Shares of the company have surged 60.6% in the past year compared with the industry’s growth of 32.7%. PEN’s earnings surpassed estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 10.54%.
Estimates for ResMed’s fiscal 2025 EPS have risen 2.7% in the past 30 days. Shares of the company have surged 86.3% in the past year compared with the industry’s 32.1% growth. RMD’s earnings surpassed estimates in each of the trailing four quarters, the average beat being 6.4%. In the last reported quarter, it delivered an earnings surprise of 8.4%.